Evidence map›Paper›PMID 30778705›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019

Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe.

C Bonnave, D Mertens, W Peetermans, K Cobbaert, B Ghesquiere, M Deschodt, J Flamaing

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Antibiotics (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

C BonnaveDepartment of Geriatrics, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
D MertensDepartment of Geriatrics, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
W PeetermansDepartment of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
K CobbaertDepartment of Geriatrics, AZ Delta Roeselare, Roeselare, Belgium.
B GhesquiereDepartment of Geriatrics, AZ Delta Roeselare, Roeselare, Belgium.
M DeschodtDepartment of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.
J FlamaingDepartment of Geriatrics, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Johan.flamaing@uzleuven.be.
KU Leuven · BEAZ Delta · BEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumococcal disease constitutes a major global health problem. Adults aged over 50 years and younger adults with specific chronic health conditions are at risk for invasive pneumococcal disease, associated with substantial morbidity and mortality. In Europe, two vaccine types are used in adults for pneumococcal immunization: pneumococcal polysaccharide vaccine (PPV23) and pneumococcal conjugate vaccine (PCV13). To provide an overview and to compare the national guidelines for pneumococcal immunization for adults in Europe. In November 2016, national guidelines on pneumococcal vaccination for adults of 31 European countries were obtained by Google search, the website of European Centre for Disease Prevention and Control, and contacting public health officials. In our analysis, we distinguished between age-based and risk-based guidelines. In October 2017, we used the same method to retrieve guideline updates. We observed great variability regarding age, risk groups, vaccine type, and use of boosters. In age-based guidelines, vaccination is mostly recommended in adults aged over 65 years using PPV23. Boosters are generally not recommended. An upper age limit for vaccination is reported in three countries. In the immunocompromised population, vaccination with both vaccines and administration of a booster is mostly recommended. In the population with chronic health conditions, there is more heterogeneity according vaccine type, sequence, and administration of boosters. Asplenia is the only comorbidity for which all countries recommend vaccination. The great variability in European pneumococcal vaccination guidelines warrants European unification of the guidelines for better control of pneumococcal disease.

Indexed as

Practice Guidelines as TopicAgedAge FactorsEuropeHumansImmunocompromised HostMiddle AgedPneumococcal InfectionsPneumococcal VaccinesRisk FactorsStreptococcus pneumoniaeVaccination13-valent pneumococcal vaccine23-valent pneumococcal capsular polysaccharide vaccinePneumococcal VaccinesAdultsEuropePCV13Pneumococcal vaccinationPPV23Recommendations

Identifiers

PMID30778705
OpenAlexW2916284457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.